BACKGROUND: Skeletal muscle atrophy and decreased expression of slow fibers contribute to exercise capacity limitation in Chronic Heart Failure (CHF). Pro-inflammatory cytokines and free radicals worsen muscle damage. In CHF sarcomeric proteins are oxidized with reduction of muscle twitch efficiency, and VO(2)-max. Beta-blockers with anti-oxidative capacity such as carvedilol have been shown to prevent contractile protein oxidation in CHF rats. Recently a new class of beta-blockers with NO donor activity has been introduced and approved for the treatment of CHF. Since a clinical clear superiority of a beta-blocker has never been shown, we compared nebivolol, that possesses NO donor activity, with bisoprolol, looking at possible differences in skeletal muscle that may have an impact on muscle function and exercise capacity in humans. We therefore studied skeletal muscle apoptosis and wastage, sarcomeric protein composition and oxidation, and muscle efficiency. METHODS AND RESULTS: In the monocrotaline rat model of CHF we compared nebivolol a beta-blocker with vasodilative properties mediated by NO production, with bisoprolol. Nebivolol prevented protein oxidation, while bisoprolol did it only partially, as demonstrated by the oxyblot analysis (Oxy/RP values) (0.90+/-0.14 Controls.; 1.7+/-0.14 CHF; 1.1+/-0.05 bisoprolol; 0.82+/-0.17 nebivolol low; 0.62+/-0.10 nebivolol high). Only nebivolol improved twitch force production and relaxation. Nebivolol prevented fibers shift towards fast isoforms, atrophy, decreased apoptosis and sphingosine levels. CONCLUSIONS: Nebivolol seems better than bisoprolol in CHF by decreasing apoptosis and cytokines induced muscle wastage, preventing fibers shift and protein oxidation. Nebivolol by stimulating NO generation may have prevented protein oxidation. It could be speculated that ROS release, pro-inflammatory cytokines production and NF-kappa-B activation may play a key role. These positive changes could produce a favorable impact on exercise capacity in man. Copyright (c) 2009 Elsevier Ireland Ltd. All rights reserved.
BACKGROUND: Skeletal muscle atrophy and decreased expression of slow fibers contribute to exercise capacity limitation in Chronic Heart Failure (CHF). Pro-inflammatory cytokines and free radicals worsen muscle damage. In CHF sarcomeric proteins are oxidized with reduction of muscle twitch efficiency, and VO(2)-max. Beta-blockers with anti-oxidative capacity such as carvedilol have been shown to prevent contractile protein oxidation in CHFrats. Recently a new class of beta-blockers with NO donor activity has been introduced and approved for the treatment of CHF. Since a clinical clear superiority of a beta-blocker has never been shown, we compared nebivolol, that possesses NO donor activity, with bisoprolol, looking at possible differences in skeletal muscle that may have an impact on muscle function and exercise capacity in humans. We therefore studied skeletal muscle apoptosis and wastage, sarcomeric protein composition and oxidation, and muscle efficiency. METHODS AND RESULTS: In the monocrotalinerat model of CHF we compared nebivolol a beta-blocker with vasodilative properties mediated by NO production, with bisoprolol. Nebivolol prevented protein oxidation, while bisoprolol did it only partially, as demonstrated by the oxyblot analysis (Oxy/RP values) (0.90+/-0.14 Controls.; 1.7+/-0.14 CHF; 1.1+/-0.05 bisoprolol; 0.82+/-0.17 nebivolol low; 0.62+/-0.10 nebivolol high). Only nebivolol improved twitch force production and relaxation. Nebivolol prevented fibers shift towards fast isoforms, atrophy, decreased apoptosis and sphingosine levels. CONCLUSIONS:Nebivolol seems better than bisoprolol in CHF by decreasing apoptosis and cytokines induced muscle wastage, preventing fibers shift and protein oxidation. Nebivolol by stimulating NO generation may have prevented protein oxidation. It could be speculated that ROS release, pro-inflammatory cytokines production and NF-kappa-B activation may play a key role. These positive changes could produce a favorable impact on exercise capacity in man. Copyright (c) 2009 Elsevier Ireland Ltd. All rights reserved.
Authors: Rob C I Wüst; David S Myers; Rachel Stones; David Benoist; Philip A Robinson; John P Boyle; Chris Peers; Ed White; Harry B Rossiter Journal: Am J Physiol Heart Circ Physiol Date: 2011-10-28 Impact factor: 4.733
Authors: Raquel Santilone Bertaglia; Joyce Reissler; Francis Silva Lopes; Walter Luiz Garrido Cavalcante; Fernanda Regina Carani; Carlos Roberto Padovani; Sergio Augusto Rodrigues; Antônio Carlos Cigogna; Robson Francisco Carvalho; Ana Angélica Henrique Fernandes; Marcia Gallacci; Maeli Dal Pai Silva Journal: J Mol Histol Date: 2011-04-21 Impact factor: 2.611
Authors: Aline V Bacurau; Telma F Cunha; Rodrigo W Souza; Vanessa A Voltarelli; Daniele Gabriel-Costa; Patricia C Brum Journal: Oxid Med Cell Longev Date: 2016-01-19 Impact factor: 6.543
Authors: Vanessa A Voltarelli; Luiz R G Bechara; Aline V N Bacurau; Katt C Mattos; Paulo M M Dourado; Carlos R Bueno; Dulce E Casarini; Carlos E Negrao; Patricia C Brum Journal: J Cell Mol Med Date: 2014-03-13 Impact factor: 5.310